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Abstract
This study aims to review the literature on eco-
nomic evaluation of childhood varicella vacci-
nation programs and to discuss how heterogene-
ity in methodological aspects and estimation of 
parameters can affect the studies’ results. After 
applying the inclusion criteria, 27 studies pub-
lished from 1980 to 2008 were analyzed in rela-
tion to methodological differences. There was 
great heterogeneity in the perspective adopted, 
evaluation of indirect costs, type of model used, 
modeling of the effect on herpes zoster, and esti-
mation of vaccine price and efficacy parameters. 
The factor with the greatest impact on results 
was the inclusion of indirect costs, followed by 
the perspective adopted and vaccine price. The 
choice of a particular methodological aspect or 
parameter affected the studies’ results and con-
clusions. It is essential that authors present these 
choices transparently so that users of economic 
evaluations understand the implications of such 
choices and the direction in which the results of 
the analysis were conducted.
Cost-Effectiveness Evaluation; Costs and Cost 
Analysis; Immunization Programs; Chickenpox
Introduction
The exponential growth of health expenditures 
resulting from the development and incorpora-
tion of new technologies puts huge pressure on 
government budgets and has sparked increasing 
interest in economic evaluation studies.
Economic evaluation, as an institutionalized 
practice, proposes to identify, quantify, assess, 
and compare the costs and consequences of 
two technologies to be considered. The tool has 
contributed to greater technical and allocative 
efficiency in the use of resources in the health 
system.
Despite the potential usefulness of economic 
evaluation in the decision-making process, it 
rarely occurs, even in countries where health 
technology evaluation agencies provide this type 
of analysis to administrators. Various character-
istics of the political spheres where decisions are 
made appear to hamper the use of cost-effective-
ness analyses. The main characteristics relate to 
limitations in the capacity to generate, access, 
and interpret the information contained in eco-
nomic analyses 1. The difficulty in understanding 
such analyses is aggravated by the wide variation 
in methodologies used.
Using economic evaluations of varicella as 
an example, the current article points to hetero-
geneity in the following methodological aspects: 
perspective, assessment of indirect costs, type of 
model, modeling of the effect on herpes zoster, 
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and estimation of the vaccine’s price and efficacy 
parameters.
Two previous reviews 2,3 of economic evalua-
tions of varicella vaccination programs described 
the data and study methodologies with the aim 
of recommending the best vaccination strategies 
(children, health workers, and other risk groups) 
to policymakers.
The current study aims to review the litera-
ture on economic evaluation of childhood vari-
cella vaccination programs, identify and discuss 
how the heterogeneity in the methodologies or 
estimates of parameters can impact the studies’ 
results.
The article begins by reviewing the uncer-
tainties concerning methodological aspects and 
estimates of parameters and how they can affect 
the results of analyses.
Perspective adopted in the analysis
The choice of perspective is the most important 
point in the analysis, since it determines which 
costs are included and how they are assessed 4. 
The healthcare provider or payer’s perspective 
(for example, in Brazil, the Unified National 
Health System or SUS) includes all the direct 
medical costs, such as consultations, hospital-
izations, medication, and lab tests. Society’s per-
spective includes direct medical costs, plus non-
medical costs, like transportation to the health 
service and indirect costs or loss of productivity 
related to the illness, as well as family expenses. 
Society’s perspective is more comprehensive and 
identifies all the costs and benefits, regardless of 
who covers the costs or who receives the benefits. 
There are strong normative arguments that favor 
adopting society’s perspective 5. Such arguments 
are related to the principles of social welfare eco-
nomic theory, according to which when a change 
in a given policy leads to a series of effects in dif-
ferent individuals and groups, the overall evalu-
ation of the policy’s efficiency requires consider-
ing all of these implications 6. Although society’s 
point of view is generally recommended, deci-
sion-makers are more interested in the health 
payer’s perspective, because these are the values 
that directly impact the health systems’ budget.
Economic evaluations that adopt society’s 
perspective favor the vaccine’s cost-effective-
ness.
Indirect costs
A sick child can generate numerous costs for the 
parents, including stress, sleep deprivation, fam-
ily breakdown, and loss of income. Many of these 
costs, related to pain, suffering, and jeopardized 
quality of life, classified as intangible costs, are 
not monetary and are difficult to measure.
Economic analyses in health generally in-
clude two categories of costs: direct and indirect. 
Briefly, direct costs are defined as all the economic 
consequences directly related to the use of health 
interventions. Indirect costs are generally related 
to loss of productivity and family expenditures.
There are two main sources of indirect costs 
in immunization programs. First, loss of time 
at work related to the vaccination process itself 
(vaccine, screening and serological testing, ad-
verse effects). Second, productivity gains due to 
the reduction in employees’ morbidity and mor-
tality, or in the specific case of childhood vac-
cination programs, the reduction in the number 
of workdays missed by parents to care for their 
sick children.
Averted losses of productivity have a major 
impact on the economic profile of childhood 
vaccination programs, where most of the savings 
are generated by reduction in the parents’ work 
absenteeism. Economic evaluations that include 
indirect costs in their analysis favor incorpora-
tion of the vaccine.
Choice of model – static versus dynamic
The models can be divided into two main catego-
ries: static (decision trees and Markov models) 
and dynamic. The principal difference between 
these categories is that in static models, the force 
of infection (the rate at which susceptible individ-
uals become infected) is a fixed parameter, con-
stant over time, and no interactions are observed 
between individual and population dynamics of 
the disease. In dynamic models, the force of in-
fection depends on the number of susceptible 
individuals in the given population 7,8.
Thus, when the possibility of change exists 
in the force of infection after immunization (i.e., 
vaccination blocks transmission of the infection 
and coverage is expected to be relatively high), 
dynamic models should be considered 9.
Dynamic models manage to include herd 
immunity in their analysis (i.e., indirect protec-
tion of susceptible individuals when a large pro-
portion of the population has been vaccinated). 
When herd immunity is considered in the mod-
eling, vaccination has a greater impact on effec-
tiveness and thus on cost-effectiveness.
Modeling the effect of varicella vaccination
on herpes zoster
The effect of introducing universal childhood 
varicella vaccination on the incidence of herpes 
zoster in the population with latent infection 
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with varicella zoster virus is still not clear. There 
are currently two opposing arguments. Accord-
ing to the first, re-exposure to the virus (contact 
with varicella) stimulates the specific immunity 
in individuals with latent infection, protecting 
them against zoster. In this case, universal vari-
cella vaccination, decreasing the circulation of 
the wild virus in the population, can lead to a sig-
nificant increase in the number of zoster cases 
in the short and medium term (as long as there 
are individuals with latent wild virus infection in 
the population). Thus, varicella immunization 
programs may be harmful to public health, since 
the gain in the reduction of varicella morbidity 
may be cancelled out by the increase in zoster 
morbidity. According to the second argument, 
re-exposure to the wild virus is not a decisive fac-
tor in the maintenance of specific immunity and 
protection against herpes zoster, and thus the in-
cidence of herpes zoster would not be affected by 
a varicella vaccination program 10.
The results of models that include the im-
pact on zoster suggest that the odds of vaccina-
tion proving cost-effective are very small. Thus, 
choice of the model can have a profound ef-
fect on the estimated attractiveness of varicella 
vaccination 11. Although data from the model-
ing suggest that vaccination programs have the 
potential to modify the epidemiology of herpes 
zoster, data from the United States where a vari-
cella vaccination program was implemented in 
1995 show no evidence that such changes are 
occurring 12.
Price and efficacy of the vaccine
A single dose of the vaccine showed an efficacy of 
70 to 90% in clinical trials 13,14,15,16,17,18. However, 
a recent meta-analysis estimated less than 72.5% 
effectiveness (95%CI: 68.5-76.0%) in the real 
world 19. There is growing evidence of decreasing 
immunity following vaccination (secondary fail-
ure of vaccination), which is particularly relevant 
to public health since it can lead to an increase 
in susceptibility in older age brackets, in which 
the risk of severe disease is greater than in child-
hood 19,20,21. In 2005, in the United States, ten 
years after the implementation of the national 
varicella immunization program, the majority 
of cases occurred in vaccinated individuals 22. 
An effectiveness of approximately 85% for one 
dose of the vaccine proved insufficient to prevent 
transmission of the wild-type virus, especially in 
places like schools with extensive contact. Con-
sequently, since 2006, a second dose of the vac-
cine (administered to children from 4 to 6 years 
of age) has been indicated as part of routine im-
munization in the United States 23,24.
Methods
Search strategy to identify studies
A broad and exhaustive search strategy was ad-
opted to identify all the relevant studies. The 
PubMed, EMBASE, Scirus, Web of Science, and 
LILACS databases were searched using the key 
words “varicella” or “chickenpox” and “cost-effec-
tiveness evaluation” or “costs and cost analysis” in 
English from 1980 to December 2008.
Study selection criteria
Studies were included in the review when they 
met the following criteria:
• Study design: full economic evaluation, de-
fined as a comparative analysis of the costs and 
consequences of two alternative health interven-
tions, including cost-minimization, cost-effec-
tiveness, cost-utility, and cost-benefit analyses.
• Population: children up to 6 years of age.
• Type of intervention: program for universal 
childhood immunization against varicella.
Results
Results of literature search
After reading the abstracts and applying the in-
clusion criteria, 27 studies were retrieved and 
analyzed in relation to the previously mentioned 
methodological differences. Two more articles 
were added 25,26 from periods studied by previous 
reviews 2,3, plus four articles 27,28,29,30 published 
in 2008.
To facilitate the comparability of study re-
sults, the monetary values were converted into 
PPP dollars (Purchasing Power Parity). PPP is the 
equivalent exchange rate for the price of a basket 
of goods and services identified in two countries. 
According to the Brazilian PPP and the exchange 
rate (from Brazilian Reais or R$ to US dollars), in 
2008, US$88 could purchase the same basket of 
goods and services in Brazil that US$100 could 
purchase in the United States.
The study results’ monetary values were 
corrected to November 2008 according to each 
country’s inflation rates. Next, all these values 
were converted into current currencies and trans-
formed into dollars, using the exchange rate pre-
sented in the World Bank report, called the ICP 
(International Comparison Program) available on 
the World Bank website 31. Finally, the amounts in 
US dollars were converted into PPP dollars.
When the study failed to specify the cost year, 
it was assumed to be two years prior to the study’s 
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publication. This strategy has been used previ-
ously in the literature 3.
Table 1 shows the abstracts from 27 studies 
25,26,27,28,29,30,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,
48,49,50,51,52 listed by year of publication (from 
the oldest to the most recent). The table lists 
the authors, year of publication, country, type 
of economic analysis, comparative vaccination 
strategies, and summary measurements of the 
results converted into 2008 PPP dollars from the 
perspectives of the payer and society.
Nearly half (48%) of the studies were per-
formed in Europe, including four in Germany 
35,42,48,52, two in France 36,48, three in Spain 27,38,51, 
three in Italy 29,45,49, one in England and Wales 43, 
and one in the Slovak Republic 39. Seven studies 
were performed in North America, including five 
in the United States 26,28,32,33,34 and two in Cana-
da 40,41. One study was done in New Zealand 37, 
one in Australia 25, two in Taiwan 44,50, one in Is-
rael 46, and one in Brazil 30.
According to the authors, 10 studies conduct-
ed cost-benefit analyses, 9 cost-effectiveness 
analyses, 7 cost-benefit plus cost-effectiveness, 
and only one cost-utility analysis.
The majority of the studies (63%) adopted 
both perspectives (payer and society) 28,29,30,34,35,
36,37,40,41,42,43,44,45,46,48,50,51,52, one study included 
the patient’s perspective 44, and three did not 
conduct an analysis from society’s perspective 
25,26,41.
Considering only the values for vaccina-
tion strategies for children up to six years of age, 
from society’s perspective, the benefit-cost ra-
tios (BCR) varied from 1.23 27 to 19.33 46. From 
society’s perspective, the BCR represents the 
reduction of direct and indirect costs from the 
disease divided by the cost of the vaccination 
program. A ratio of 19.33:1 means that each dol-
lar invested in the vaccination program saves 
19.33 dollars. From the payer’s perspective, the 
incremental cost-effectiveness ratios varied from 
PPP$10.70 35 to PPP$225.60 25 per averted case 
and from PPP$3,942 34 to PPP$33,218 41 per year 
of life gained.
In Table 2, of the 27 studies that were re-
viewed, only three 25,26,41 did not include indirect 
costs in the economic analysis. The magnitude 
of indirect costs depended on the number of 
days of work missed due to varicella and the unit 
value of workday considered in the analysis. The 
estimated mean number of workdays missed by 
parents to care for their sick children varied from 
0.6 to 5 days (Table 2). The lowest value (0.6 days) 
was reported for the first time by Banz et al. 42, es-
timated from an epidemiological survey in Ger-
many. Brisson & Edmunds 43 presented the same 
figure (0.6 days) based on epidemiological stud-
ies in Europe 35,36,53, and Coudeville et al. 48 and 
Hammerschmidt et al. 52 used the same estimate 
initially reported by Banz et al. 42. The highest 
value (5 days) came from an assumption in the 
first economic evaluation study on the varicella 
vaccine 32, in 1994.
All the studies used the human capital 
model to assess missed workdays, and in most 
cases were based on the mean value of the fe-
male workday. The lowest value for workday 
missed by parents (PPP$12.70) was reported by 
Coudeville et al. 36 in France, followed by that 
reported in the Brazilian study (PPP$13.70) 30. 
The values reported by other studies varied from 
PPP$45.60 37 to PPP$326.40 28.
The proportion of indirect costs in the total 
cost of varicella varied from 42.3% 27 to 98% 34. 
The highest percentage (98%), reported by Lieu 
et al. 34, was explained by the inclusion of future 
costs related to premature death or prolonged 
disability related to varicella encephalitis in cal-
culating indirect costs. Indirect costs were also 
heavily related to domestic policies and regula-
tions. In the specific case of Germany, where a 
domestic policy requires health plans to reim-
burse parents for approximately 90% of the costs 
of workdays missed to care for sick children 52, 
indirect costs were also included in the health 
payer’s perspective 42.
Table 3 summarizes the various models’ char-
acteristics. Of all the studies reviewed, 10 used 
dynamic models 29,30,36,40,42,43,45,48,51,52, 16 used 
static models 25,26,27,28,32,33,34,35,38,39,41,44,46,47,49,50, 
and one study used a pseudodynamic model 37. 
The latter model was considered pseudodynamic 
because it did not incorporate the indirect effects 
of vaccination on the entire population, but ap-
pears to have applied reduced forces of infection 
to susceptible individuals in the vaccinated co-
horts 2.
Most of the dynamic models 29,36,42,45,51,52 
were based on the initial dynamic model devel-
oped by Halloran et al. 54, and the others 30,40,43,48 
were based on similar approaches. All the dy-
namic models included the indirect effects of 
vaccination on non-vaccinated individuals (herd 
immunity) in the analysis. The study 44 with the 
Markov model succeeded in simulating the force 
of infection and attack rate by age bracket in the 
non-vaccinated group. Another study 46 with a 
static model reported the partial inclusion of 
herd immunity, but the article failed to specify its 
modeling methodology.
Only three studies 26,40,43 included the ef-
fect of vaccination on zoster. In the two studies 
by Brisson & Edmunds 40,43, the dynamic mod-
els assumed that contact with varicella would 
stimulate immunity against zoster for 20 years, 
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Table 1
Economic evaluations of universal childhood vaccination programs against varicella.
Reference/Year of 
publication
Country Type of analysis * Vaccination 
strategy
Payer’s perspective Society’s perspective
Preblud et al. 32/1985 USA Cost-benefi t 15 months BCR = 0.30:1 ** BCR = 6.90:1 **
Huse et al. 33/1994 USA Cost-benefi t 15 months NP NPV = 101.2 per vaccinated 
individual
Lieu et al. 34/1994 USA Cost-benefi t/Cost-
effectiveness
< 6 years BCR = 0.90:1
3.3 per CA; 3,942 per 
LYS
BCR = 5.40:1
Beutels et al. 35/1996 Germany Cost-benefi t 15 months BCR = 0.82:1
23.1 per CA; 22.145 
per LYS
BCR = 4.60:1
Cost-effectiveness 15 months and 
catch-up
BCR = 0.92:1
10.7 per CA; 7,759 per 
LYS
BCR = 4.72:1
Coudeville et al. 36/1999 France Cost-benefi t < 6 years NP ANB = 374,898,339
Scuffham et al. 37/1999 New Zealand Cost-effectiveness 15 months 31.8 per CA (27.6) per CA ***
Díez-Domingo et al. 
38/1999
Spain Cost-benefi t 15 months BCR = 0.54:1 ** BCR = 1.61:1 **
Scuffham et al. 25/1999 Australia Cost-effectiveness 12 months 29.2 per CA NP
12 months and 
catch-up
225.6 per CA NP
Hudeckova et al. 39/2000 Slovak 
Republic
Cost-benefi t/Cost-
effectiveness
Newborns BCR = 0.20:1 BCR = 1.45:1
Brisson & Edmunds 
40/2002
Canada Cost-effectiveness Without zoster
1 year 46.482 per DYLS BCR = 5.24:1 **
1 year and catch-up 53,128 per DYLS BCR = 4.90:1 **
With zoster
1 year 123,443 per DYLS NP
1 year and catch-up 156,662 per DYLS NP
Getsios et al. 41/2002 Canada Cost-effectiveness 12 months 39.3 per CA; 33,218 
per YLS
Economical #
Banz et al. 42/2003 Germany Cost-benefi t/Cost-
effectiveness
1-1.5 years BCR = 1.75:1 BCR = 4.12:1
1-1.5 years and 
catch-up
BCR = 1.70:1 BCR = 4.10:1
Brisson & Edmunds 
43/2003
England and 
Wales
Cost-utility 12-15 months Dominated ## Dominated ##
12-15 months and 
catch-up
Dominated ## Dominated ##
Hsu et al. 44/2003 Taiwan Cost-benefi t 15 months BCR = 0.34:1 ** BCR = 2.06:1 **
Coudeville et al. 45/2004 Italy Cost-benefi t 1-2 years BCR = 1.20:1 BCR = 3.50:1
Cost-effectiveness 1-2 years and 
catch-up
NS NS
Ginsberg & Somekh 
46/2004
Israel Cost-effectiveness 12 months BCR = 1.63:1 BCR = 19.33:1
12 months and 
catch-up
BCR = 1.36:1 BCR = 18.80:1
Jean-Jasmin et al. 
47/2004
Singapore Cost-benefi t 15 months NP 142.2 per CA
15 months and 
catch-up
BCR = 2.25:1
Coudeville et al. 48/2005 France and
Germany
Cost-effectiveness 19 months Cost savings # Cost savings #
19 months and 
catch-up
Cost savings # Cost savings #
Goldman 26/2005 USA Cost-benefi t NS ANC = 82.2 million NP
Gialloreti et al. 49/2005 Italy Cost-effectiveness Childhood NP Savings per year = 
5,443,245Catch-up
(continues)
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Table 1 (continued)
Tseng et al. 50/2005 Taiwan Cost-benefi t 12-18 months 80.8 per CA (136.3) per CA ***
Cost-effectiveness BCR = 0.54:1** BCR = 1.45:1 **
Lenne et al. 51/2006 Spain Cost-effectiveness 1-2 years 5,197 per LYS NS
1-2 years and 
catch-up
17,372 per LYS 11,273 per LYS
Hammerschmidt et al. 
52/2007
Germany Cost-benefi t 11-23 months and 
catch-up
BCR = 1.08:1 ** BCR = 2.56:1 **
Pérez-Rubio et al. 
27/2008
Spain Cost-benefi t 15 months NP BCR = 1.23:1
Zhou et al. 28/2008 USA Cost-benefi t 1 dose; 12-15 
months
BCR = 1:1 BCR = 4.37:1
Cost-effectiveness 2 doses;12-15 
months
BCR = 0.61:1 BCR = 2.73:1
Bonanni et al. 29/2008 Italy Cost-benefi t 1-1.5 years BCR = 0.67:1 ** BCR = 3.47:1 **
1-1.5 years and 
catch-up
BCR = 0.64:1 ** BCR = 3.33:1 **
Valentim et al. 30/2008 Brazil Cost-effectiveness 12 months 28.1 per CA 31.6 per CA
12,962 per LYS 14,573 per LYS
Note: all costs in PPP (Purchasing Power Parity) dollars for 2008.
LYS: life year saved; DLYS: discounted life year saved; NPV: net present value; ANB: actualized net benefi t; CA: case averted; ANC: annual net costs; NP: not 
performed; NS: not specifi ed; BCR: benefi t-cost ratio.
* As reported by the author;
** This ratio included only costs, not health benefi ts. From the payer’s perspective, it is the reduction in the direct costs of the disease divided by the cost of 
the vaccination program. From society’s perspective, it is the reduction in the direct and indirect costs (loss of productivity) from the disease, divided by the 
cost of the vaccination program. A ratio of 6.9:1 means that each dollar invested in the vaccination program saves 6.9 dollars;
*** The incremental cost-effectiveness ratios (ICER) are negative because the strategies generate savings (they are cheaper than the current strategy) and 
generate more health benefi ts;
# The two strategies are cost savings (they are cheaper than the current strategy) and generate more health benefi ts;
## The two strategies are dominated (they are more expensive than the current strategy) and generate fewer health benefi ts.
Reference/Year of 
publication
Country Type of analysis * Vaccination 
strategy
Payer’s perspective Society’s perspective
and thus modeled the increase in the number of 
cases, hospitalizations, and deaths from herpes 
zoster resulting from vaccination.
In Goldman 26, the static model also assumed 
that exposure to the wild-type varicella virus 
would stimulate immunity, protecting against re-
activation of herpes zoster, and thus vaccination 
against varicella would increase the incidence of 
herpes zoster. The model predicted the number 
of herpes zoster cases and the associated direct 
medical costs 30 years after the introduction of 
vaccination. Goldman calculated that after 50 
years, the vaccination program would reach the 
break-even point, and that net medical savings 
would accrue from that point onward.
The vaccine prices listed in Table 4 refer only 
to the dose price and do not include other costs 
associated with vaccination, such as materials 
(needles and syringes), overhead, waste, and 
treatment of adverse events. We chose to present 
only the price of the vaccine, because the other 
components are highly subject to the organiza-
tion of each country’s health systems. The vaccine 
price per dose varied greatly, from PPP$8.31 to 
PPP$109.21. Ginsberg & Somekh 46 reported the 
lowest dose price, explained by the use of a quota 
for an importer of large volumes. The highest price 
was used in the evaluation by Gialloretti et al. 49.
Most of the studies used data for the single-
antigen vaccine. Only two studies 28,52 used data 
from the quadrivalent vaccine (MMRV) against 
measles, mumps, rubella, and varicella. The vast 
majority of the studies reported efficacy data 
(percentage of risk reduction in vaccinated in-
dividuals as observed in clinical trials). Very few 
studies 28,52 applied data on effectiveness (per-
centage of risk reduction in vaccinated individu-
als, as observed in the real world). The efficacy 
rates varied from 85% 30,50 to 100% 27. The lowest 
effectiveness (85%) reflected the use of results 
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from studies following introduction of the vac-
cine in the United States 55,56, while the most op-
timistic used data from an older clinical trial 13. In 
studies that used the MMRV vaccine, Hammer-
schmidt et al. 52 assumed a 95% efficacy for two 
doses of vaccine, based on the opinion of experts. 
Zhou et al. 28 assumed an effectiveness of 93% for 
two doses of vaccine, based on the breakthrough 
rates (primary vaccination failure) among indi-
viduals vaccinated with 1 and 2 doses 57.
As a consequence of the U.S. recommenda-
tion of a second dose of vaccine in 2006, three 
more recent studies analyzed the two-dose vac-
cine strategy 28,29,52.
Vaccination coverage rates varied from 10% 37 
to 100% 26,27,52. The lowest coverage rate, 10%, 
represented private sector coverage based on the 
payer’s perspective in the analysis 37. Goldman 26 
assumed 100% coverage, because vaccination 
became mandatory in many American states. 
The highest coverage rates were applied by those 
that assumed the same coverage obtained for the 
triple vaccine 27 or used the MMRV vaccine 52.
Of the 13 studies that reported the rate of 
decrease in post-vaccination immunity, seven 
(54%) used the 3.1% annual rate from the studies 
by Brisson et al. 10,58. Four studies used the rate 
reported by Halloran et al. 54, where 15% of the 
Table 2
Characteristics of indirect costs included in studies from society’s perspective.
 Reference/Year of Number of workdays Cost per workday Indirect costs as % of
 publication missed * missed total cost
 Preblud et al. 32/1985 5 104.7 95.0
 Huse et al. 33/1994 3.7 156.8 75.7
 Lieu et al. 34/1994 NS 316.9 98.0
 Beutels et al. 35/1996 2.6 224.4 95.0 **
 Coudeville et al. 36/1999 3.4 12.7 NS
 Scuffham et al. 37/1999 3 45.6 75.9 **
 Díez-Domingo et al. 38/1999 1.19 64.1 69.9
 Scuffham et al. 25/1999 NI NI NI
 Hudeckova et al. 39/2000 NS NS 68.9 **
 Brisson & Edmunds 40/2002 1.7-1.2 *** 81.47-69.98 86.9
 Getsios et al. 41/2002 3.7 36.1 61.9
 Banz et al. 42/2003 0.6 217.9 72.5
 Brisson & Edmunds 43/2003 0.6 54.9 43.0 **
 Hsu et al. 44/2003 1.85 103.5 72.2
 Coudeville et al. 45/2004 0.7 162.7 61.1
 Ginsberg & Somekh 46/2004 2.5 256.2 *** 92.2
 Jean-Jasmin et al. 47/2004 1.6 67.2 77.6
 Coudeville et al. 48/2005 0.7-0.6 # 202.5-222.8 # 70.5-74.0
 Goldman 26/2005 NI NI NI
 Gialloreti et al. 49/2005 0.6 102.2 65.0
 Tseng et al. 50/2005 3.7 76.2 42.9
 Lenne et al. 51/2006 0.97 100.7 71.5
 Hammerschmidt et al. 52/2007 0.6 217.9 51.5
 Pérez-Rubio et al. 27/2008 NS NS 42.3
 Zhou et al. 28/2008 NS 326.4 NS
 Bonanni et al. 29/2008 0.8 163.5 81.4
 Valentim et al. 30/2008 0.27 13.7 47.3
Note: all costs in PPP (Purchasing Power Parity) dollars for 2008.
NS: not specifi ed; NI: not included.
* Mean number of workdays missed by parents or caregivers per episode of varicella;
** Percentage of savings;
*** 1.7 for children 1-4 years of age and 1.2 for children 5-15 years of age;
# 0.7, 202.5, and 70.5 in Germany and 0.6, 222.8, and 74 in France.
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successfully vaccinated individuals had lost their 
immunity by the end of life.
Adverse events were either found at what 
were considered low rates, ranging from 0.1% 32 
to 3.6% 37, or were not considered in the analy-
ses. Five studies 26,27,39,47,52 did not specify the 
adverse event rate.
Table 5 shows the most frequent factors that 
significantly altered the results of the analyses. 
The factor with the greatest impact on the results 
was the inclusion of indirect costs, followed by 
the perspective (society versus payer) and vac-
cine price.
Some studies reported additional factors, 
such as vaccine coverage 29,34,35,36,45,51,52, dis-
count rate 25,28,29,37,40,41,42,43,46,52, health benefits 
discount 42, time horizon 43, and second dose of 
vaccine 27,30.
Discussion
According to this review, the perspective adopted 
in the economic evaluations affected the stud-
ies’ outcome. Where society’s perspective was 
chosen, the vaccination programs were found to 
be a cost-effective strategy. This confirmed the 
findings by Thiry et al. 2, whereby the attractive-
ness of childhood vaccination was also affected 
by the perspective adopted for analysis. Accord-
ing to these authors, despite the models’ varying 
data and assumptions, the studies suggested that 
from society’s perspective, universal vaccination 
at 12 or 15 months of age proved quite attractive 
since it generated major savings by reducing the 
number of workdays missed by parents. Howev-
er, from the payer’s point of view, vaccination did 
not generate savings. Likewise, Rozenbaum et 
al. 3 stated that from society’s perspective, child-
Table 3
Model’s characteristics.
 Reference/Year of Type of model Inclusion of herd  Inclusion of impact of 
 publication  immunity vaccination
    on zoster
 Preblud et al. 32/1985 Static No No
 Huse et al. 33/1994 Static No No
 Lieu et al. 34/1994 Static Yes No
 Beutels et al. 35/1996 Static No No
 Coudeville et al. 36/1999 Dynamic Yes No
 Scuffham et al. 37/1999 Pseudodynamic Partially No
 Díez-Domingo et al. 38/1999 Static No No
 Scuffham et al. 25/1999 Static No No
 Hudeckova et al. 39/2000 Static No No
 Brisson & Edmunds 40/2002 Dynamic Yes Yes
 Getsios et al. 41/2002 Static No No
 Banz et al. 42/2003 Dynamic Yes No
 Brisson & Edmunds 43/2003 Dynamic Yes Yes
 Hsu et al. 44/2003 Static Yes No
 Coudeville et al. 45/2004 Dynamic Yes No
 Ginsberg & Somekh 46/2004 Static Partially No
 Jean-Jasmin et al. 47/2004 Static No No
 Coudeville et al. 48/2005 Dynamic Yes No
 Goldman 26/2005 Static No Yes
 Gialloreti et al. 49/2005 Static No No
 Tseng et al. 50/2005 Static No No
 Lenne et al. 51/2006 Dynamic Yes No
 Hammerschmidt et al. 52/2007 Dynamic Yes No
 Pérez-Rubio et al. 27/2008 Static No No
 Zhou et al. 28/2008 Static No No
 Bonanni et al. 29/2008 Dynamic Yes No
 Valentim et al. 30/2008 Dynamic Yes No
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Table 4
Vaccine assumptions in economic analyses of varicella.
 Reference/Year Dose price (PPP) Efficacy (%) Number Vaccination Annual Adverse
 de publication   of doses coverage waning effects (%)
      rate (%)
 Preblud et al. 32/1985 26.19 90.0 1 90 NC 0.1
 Huse et al. 33/1994 53.31 95.0 1 NS NS 1.0
 Lieu et al. 34/1994 55.20 90.0 1 97 15.0 * 2.0
 Beutels et al. 35/1996 84.16 90.0 1 70 15.0 * NC
 Coudeville et al. 36/1999 20.53 90.0 1 80 15.0 * 1.0
 Scuffham et al. 37/1999 51.38 95.0 1 10. 80 ** NC 3.6
 Díez-Domingo et al. 38/1999 40.10 90.0 1 95 NC 2.0
 Scuffham et al. 25/1999 52.49 95.0 1 80 NC 1.8
 Hudeckova et al. 39/2000 29.12 90.0 1 NS NC NS
 Brisson & Edmunds 40/2002 62.67 *** 90.0 1 90 3.1 NC
 Getsios et al. 41/2002 61.98 90.0 1 85 15.0 * 0.3
 Banz et al. 42/2003 73.86 86.0 1 85 0.5 2.0
 Brisson & Edmunds 43/2003 54.92 90.0 1 90 3.1 NC
 Hsu et al. 44/2003 82.11 95.0 1 95 NS 2.0
 Coudeville et al. 45/2004 50.64 97.0 1 90 3.1 1.5
 Ginsberg & Somekh 46/2004 8.31 87.6 1 94 3.1 2.0
 Jean-Jasmin et al. 47/2004 58.78 90.0 1 NS NC NS
 Coudeville et al. 48/2005 61.44-67.52 # 97.0 1 90 3.1 1.5
 Goldman 26/2005 NS 100.0 1 100 NS NS
 Gialloreti et al. 49/2005 109.21 NS 1 90 NC NC
 Tseng et al. 50/2005 43.71 85.0 1 80 NC 2.0
 Lenne et al. 51/2006 40.40 97.0 1 97 3.1 1.0
 Hammerschmidt et al. 52/2007 55.53 95.0 2 90-100 ## 0.5 NS
 Pérez-Rubio et al. 27/2008 39.49 100.0 ### 1 100 NS NS
 Zhou et al. 28/2008 60.31-70.82 § 93.0 2 95 NC 1.0-0.5 §§
 Bonanni et al. 29/2008 45.99 90.0-93.0 §§§ 2 85 3.0 2.0
 Valentim et al. 30/2008 37.96 85.0 1 80 NC NC
NC: not considered; NS: not specifi ed; PPP: purchasing power parity.
* 15% of successfully vaccinated individuals will have their immunity exhausted by the end of their lives;
** 10% from the consumer’s perspective and 80% from society’s perspective;
*** In addition to the price of the vaccine dose, administration, storage, reserve vaccines, transportation, materials, and other costs;
# 61.44 in France and 67.52 in Germany;
## 90% after fi rst dose and 100% after second dose;
### In the fi rst year of life;
§ 60.31 for the public sector and 70.82 for the private sector;
§§ 1% after fi rst dose and 0.5% after second dose;
§§§ 90% after fi rst dose and 93% after second dose.
hood vaccination programs have always saved 
costs, with the exception of those that took the 
potential impact on herpes zoster into account.
Despite the important debate in the literature 
on the most appropriate method (human capi-
tal versus friction cost) for assessing social losses 
resulting from the disease 59, all the studies used 
the human capital method to assess the workday 
value. The variability in the value of the workday 
lost by parents, from PPP$12.70 to PPP$326.40 28, 
highlights the wide variation in wage scales be-
tween the different countries studied.
Although PPP supposedly corrects these 
differences in price levels, it fails to completely 
cancel out these disparities. Thus, in the more 
economically developed countries, where wages 
are higher, the analyses are more favorable to in-
troduction of the vaccine, because the amount 
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of indirect costs saved is higher, thus underscor-
ing one of the main critiques of the human capi-
tal method, which assesses productivity based 
on income. The vaccine proved more attractive 
where wages are higher, because according to the 
human capital method, persons are worth what 
they produce for society.
To determine the impact of indirect costs on 
total cost of varicella, indirect costs as a propor-
tion of the total cost of the disease were present-
ed. The results should be interpreted with cau-
tion, because the definition of indirect costs dif-
fered somewhat between studies and because the 
measurement and assessment of indirect costs 
varied greatly. While some studies only included 
losses of productivity in the form of workdays lost 
by parents to care for their children, others also 
included the cost of death or prolonged disability 
resulting from the disease.
Estimation of the number of workdays 
lost also varied between studies. While some au-
thors 48,52 repeated the value (0.6 days) initially 
reported by Banz et al. 42 or presented the same 
value 43 as in epidemiological studies conducted 
in Europe 35,36,53, others assumed a higher figure 
(5 days). It was not surprising that the highest 
percentage of indirect costs in the total cost of 
varicella (98%) 34 was associated with the second 
highest cost of a workday (PPP$316.90). Overes-
timation of these data biases the results of the 
analysis in favor of the vaccine.
The definition of indirect cost determines 
which values will be included in its calculation. 
Together with the value of the workday, they can 
have a huge impact on the results of the analy-
sis. All evaluations that included indirect costs 
in their calculation favored the vaccination pro-
gram, and the higher the value attributed to in-
Table 5
Impact of methodology and parameters on the results of economic analyses for varicella.
 Reference/Year Perspective Indirect Model Herpes Vaccine Vaccine
 de publication  costs  zoster price efficacy
 Preblud et al. 32/1985 Yes Yes   Yes 
 Huse et al. 33/1994  Yes    
 Lieu et al. 34/1994 Yes Yes   Yes 
 Beutels et al. 35/1996 Yes Yes    Yes
 Coudeville et al. 36/1999 Yes Yes Yes   
 Scuffham et al. 37/1999 Yes Yes   Yes Yes
 Díez-Domingo et al. 38/1999 Yes Yes    
 Scuffham et al. 25/1999     Yes 
 Hudeckova et al. 39/2000  Yes    
 Brisson & Edmunds 40/2002 Yes Yes Yes Yes Yes Yes
 Getsios et al. 41/2002     Yes 
 Banz et al. 42/2003  Yes Yes  Yes 
 Brisson & Edmunds 43/2003   Yes Yes  Yes
 Hsu et al. 44/2003 Yes Yes   Yes 
 Coudeville et al. 45/2004   Yes  Yes 
 Ginsberg & Somekh 46/2004  Yes   Yes 
 Jean-Jasmin et al. 47/2004  Yes    
 Coudeville et al. 48/2005 Alteration of all the parameters did not modify the result of the analysis
 Goldman 26/2005    Yes  
 Gialloreti et al. 49/2005 Did not analyze sensitivity of the parameters.
 Tseng et al. 50/2005 Yes Yes    
 Lenne et al. 51/2006 Yes Yes Yes   
 Hammerschmidt et al. 52/2007  Yes Yes   
 Pérez-Rubio et al. 27/2008 Yes Yes    
 Zhou et al. 28/2008 Yes    Yes 
 Bonanni et al. 29/2008 Yes Yes Yes  Yes 
 Valentim et al. 30/2008   Yes  Yes 
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direct costs, the more favorable the incremental 
cost-effectiveness ratio (ICER).
All the economic evaluations that employed 
dynamic models included herd immunity in the 
analysis and favored the vaccination program.
Due to the complexity of developing dynam-
ic models, various authors tend to use the same 
model in different contexts. Several authors have 
used the dynamic model designed by Halloran 
et al. 54 to evaluate the cost-effectiveness of their 
vaccination programs.
This model indicated that vaccination of chil-
dren at 12 months reduced both varicella inci-
dence and hospitalization in the United States. 
However, the study investigated a small number 
of vaccination policies and coverage rates, as-
sumed optimistic vaccine efficacy rates, adopted 
an age structure that did not reflect varicella epi-
demiology precisely, and did not conduct a sen-
sitivity analysis in the “Who Acquires Infection 
from Whom” matrix (WAIFW) 36.
In addition, this model focused mainly on the 
change in varicella incidence and morbidity due 
to changes in the age at infection, and failed to 
explore the possible effects of vaccination on zos-
ter epidemiology.
These issues emphasize the importance of 
clarity in the models’ methodology and assump-
tions, as well as a justification for the choices and 
discussion of the possibility of using the same 
model in different contexts. Taking the WAIFW 
as an example, can a single matrix represent the 
age structure and contact pattern in different 
countries?
The three studies 26,40,43 that included the ef-
fect of vaccination on zoster assumed that con-
tact with varicella would stimulate immunity 
against zoster, and thus modeled the increase in 
incidence, mortality, and use of resources related 
to zoster treatment.
The model 10 adopted in the two studies by 
Brisson & Edmunds 40,43 predicted an increase 
in post-vaccination zoster incidence for a period 
of 60 years 10,40,43,60. However, they recognized 
the lack of knowledge on the mechanisms that 
trigger zoster and the model’s structure, and the 
estimated parameters are speculative and prob-
ably oversimplified.
Given the complexity and unpredictable 
interactions between childhood varicella vac-
cination and herpes zoster incidence, the saf-
est options for vaccination programs would be: 
(1) vaccination targeting adolescents, adults, 
and other high-risk susceptible groups. In this 
case, only a limited proportion of the popula-
tion is vaccinated, and there is no impact on 
either virus transmission in the community or 
herpes zoster incidence; (2) vaccination against 
varicella in childhood and vaccination against 
zoster for individuals at increased risk of reac-
tivation of the varicella zoster virus. However, 
there are no economic evaluation studies on the 
concurrent introduction of the two vaccines in 
a population. Besides, the decrease in varicella 
transmission could result in a change in the age 
bracket at risk of herpes zoster. However, it is ex-
tremely important to monitor and analyze these 
two diseases, which exert a substantial impact 
on public health, in order to guarantee that vac-
cination programs are producing the expected 
benefits 12.
Any economic analysis that assumes an in-
crease in zoster incidence after varicella vacci-
nation will present unfavorable results for inclu-
sion of the vaccine. Taking Brisson & Edmunds 
40 as an example, the WAIFW nearly tripled with 
the inclusion of zoster. In the strategy based on 
vaccination of children at one year of age, the 
values ranged from PPP$46,482 to PPP$123,443, 
and in the strategy with vaccination of children 
at one year of age plus catch-up they varied from 
PPP$53,128 to PPP$156,662.
The second dose of vaccine against varicella 
is expected to reduce the number of vaccine fail-
ures and thus reduce the number of vaccinated 
individuals that remain susceptible after one 
dose of the vaccine 61. However, two doses of the 
vaccine nearly double the total cost of vaccina-
tion. If this cost increase is not compensated for 
by a reduction in the cost of vaccine failures, it 
may negatively impact the vaccination program’s 
cost-effectiveness 3.
Conclusions
In most of the studies reviewed, universal child-
hood vaccination programs against varicella 
proved to be cost-saving (i.e., generated sav-
ings) from society’s perspective. According to five 
studies 42,45,46,48,52 they were cost-saving from the 
perspectives of both society and the payer. Three 
of these studies 42,48,52 were done in Germany, 
where productivity costs are also assessed from 
the payer’s perspective.
The only studies in which childhood vaccina-
tion was not considered a cost-effective strategy 
were those that considered the increase in cases 
of post-varicella vaccination zoster 26,40,43. How-
ever, the relationship between vaccination against 
varicella in childhood and zoster incidence in the 
population with latent varicella zoster infection 
has still not been completely elucidated, and the 
results of these modeling studies are considered 
speculative. It is crucially important to conduct 
studies on the process of zoster reactivation and 
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herpes zoster surveillance following introduction 
of the varicella vaccine.
In the case of varicella, the indirect costs from 
absenteeism and loss of associated productiv-
ity are more important than the direct costs of 
treating the disease. Thus, indirect costs should 
be defined, measured, and assessed better, be-
cause the introduction of a universal childhood 
vaccination program may represent a preventive 
strategy with major social and economic impact.
Due to the complexity of varicella epide-
miology, dynamic models are recommended 
for analyzing childhood vaccination programs, 
since they are the only ones capable of model-
ing the indirect effects of vaccination, which are 
so important in determining the programs’ cost-
effectiveness.
The programs’ cost-effectiveness was heav-
ily related to the price of the vaccine used. The 
emerging concept of the need for a second dose 
of vaccine will require better negotiation efforts. 
It is possible that larger discounts on the vaccine 
price will be achieved with large purchase vol-
umes or competition between vaccine manufac-
turers, which may thus lead to a price drop.
Since the vaccine’s efficacy also played an 
important role in the programs’ cost-effective-
ness, it is recommended to use effectiveness 
data from post-vaccination studies, since they 
are more realistic than efficacy data based on 
clinical trials.
In conclusion, we observed a wide hetero-
geneity in the perspectives, assessment of indi-
rect costs, type of model, modeling of the effect 
on herpes zoster, and estimation of the vaccine 
price and efficacy parameters. The choice of a 
given methodological aspect or parameter af-
fected the studies’ results and conclusions. It is 
crucial for the authors to present these choices 
transparently, and that readers and users of eco-
nomic evaluations understand the repercussions 
of these choices, i.e., in which direction (for or 
against) the results were conducted. Since Brazil 
is currently reviewing its decision on whether or 
not universal childhood vaccination against va-
ricella should be adopted, we have the chance 
to benefit from the experience of countries that 
have already introduced the vaccine, as well as 
the results of various published economic evalu-
ation studies.
Resumo
O presente trabalho tem por objetivo rever a literatura 
sobre avaliação econômica de programas de vacinação 
infantil contra varicela, e discutir como a heterogenei-
dade em aspectos metodológicos e na estimativa dos 
parâmetros pode afetar os resultados dos estudos. Após 
aplicação dos critérios de inclusão, 27 estudos do perí-
odo de 1980 a 2008 foram analisados com relação às 
diferenças metodológicas. Observou-se grande hetero-
geneidade na perspectiva adotada, valoração dos cus-
tos indiretos, tipo de modelo empregado, modelagem 
do efeito no herpes zoster, e na estimativa dos parâme-
tros de preço e eficácia da vacina. O fator que mais im-
pactou os resultados foi a inclusão dos custos indiretos 
seguido da perspectiva e preço de vacina adotados. A 
escolha de um determinado aspecto metodológico ou 
parâmetro afetou os resultados e conclusões dos es-
tudos. É de fundamental importância que os autores 
apresentem essas escolhas com transparência para que 
os usuários das avaliações econômicas compreendam 
as repercussões dessas escolhas, e em qual direção os 
resultados das análises foram conduzidos.
Avaliação de Custo-Efetividade; Custos e Análise de 
Custo; Programas de Imunização; Varicela
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